A B S T R A C T Five patients with fasting and(or) postprandial hypoglycemia were found to have insulin antibodies in the absence of previously documented immunization. Studies on the equilibrium-binding of insulin to the autoantibodies revealed two classes of binding sites with association constants and binding capacities analogous to those of insulin antibodies from insulin-treated diabetic patients. Similarly, no consistent differences in these parameters were found in both groups of patients with insulins ofbovine, porcine, and human origin. Proinsulin (C-segment directed) antibodies capable ofbinding bovine or porcine proinsulin were present in 10 of 10 and 9 of 10 insulin-treated diabetics serving as controls, respectively, and, when present, provide incontrovertible evidence of exogenous insulin administration. No such antibodies could be detected in the hypoglycemic patients with autoimmune insulin antibodies.
INTRODUCTION
The immunogenicity of insulin in humans was first documented by Berson et al. (1) who demonstrated the existence of specific, nonprecipitating antibodies in the serum of insulin-treated diabetic patients. These antibodies have been incriminated in the pathogenesis of some forms of insulin resistance in diabetes mellitus (2) . Moreover, hypoglycemia in insulin-treated patients may arise by release of the hormone from circulating insulin-antibody complexes (3) . More recently, a number of patients with spontaneous hypoglycemia in association with insulin antibodies have been reported (4) (5) (6) (7) (8) (9) . An autoimmune origin has been proposed for these antibodies in view of the absence of a history of previous insulin administration (4) (5) (6) (7) (8) (9) and the finding of a higher affinity for human insulin (4, 5) in some, but not all of the reported cases (7) . The association of spontaneous hypoglycemia with apparent insulin autoantibodies in Graves' disease has also been described (8) .
This study is concerned with five patients who presented with a similar syndrome of severe spontaneous hypoglycemia with insulin antibodies in the absence of evidence of previous injection of insulin. The autoimmune hypothesis for the origin ofthe insulin antibodies sode of confusion, combativeness, and verbal abusiveness. She was found to have blood glucose of 35 mg/dl, and her symptoms abated completely after intravenous glucose administration. Similar symptoms, associated at times with syncope, had been present for 3 wk. For several months she had experienced terrifying nightmares from which she would wake sweating profusely. During the first day after admission to hospital, interruption of her intravenous infusion ofglucose led to a recurrence of hypoglycemia after _90 min and blood glucose levels at these times ranged between 20 and 40 mg/dl. Plasma cortisol values were normal, and an oral glucose tolerance test (GTT)l showed a diabetic curve (fasting plasma glucose (89]: 1 h, 238; 2 h, 268; 3 h, 122; 4 h, 56; and 5 h, 58 mg/dl) but neither fasting nor reactive hypoglycemia were present. Unusually high levels of serum insulin led to the demonstration of insulin antibodies.
Patient 2 is a 43-yr-old white woman of Latin-American ancestry. For 1 yr she had noted episodes of dizziness, tremulousness, and diaphoresis occurring 3.5-4 h after meals, on one or two occasions daily. Milder attacks also occurred before breakfast. The symptoms could be relieved by ingesting sugarcontaining foods. An oral GTT showed a diabetic pattern with frank reactive hypoglycemia (fasting plasma glucose [70]:
30 min, 165; 1 h, 209; 2 h, 222; 3 h, 125; 4 h, 61; and 5 h, 41 mg/dl). An 1,800-calorie diet and 250 mg chlorpropamide dailv were initiated by a private physician, but the latter medication had to be discontinued because of worsening hypoglycemia. The patient's mother was an insulin-requiring diabetic who routinely gave her a monthly intramuscular injection of vitamin B-12. Insulin administration was denied. Fasting and stimulated insulin levels were markedly elevated in the double antibody radioimmunoassay leading to the suspicion that insulin antibodies might be present. Their presence was subsequently confirmed. The patient has been described in detail (10) .
Patient 3, a 3-yr-old boy, was a product of a full-term pregnancy and cesarean section. Symptoms of hypoglycemia were not noted in the neonatal period. Between the ages of 10 and 23 mo he developed several bouts of ketotic hypoglycemia characterized by lethargy, and by one episode of seizure associated with a blood glucose of 13 mg/dl and an insulin level of 4 ,uU/ml. Remission of symptoms followed intravenous glucose. During this period he showed an appropriate hyperglycemic response to glucagon administration and had normal cortisol levels. At 25 mo several episodes of severe hypoglvcemia with ketosis occurred. Lethargy, diaphoresis, and thready pulse characterized these episodes, and they invariably led to coma unless intravenous glucose was administered. Insulin levels of 254 ,uU/ml were demonstrated at this time. At age 2.5 vr, the hypoglycemic attacks were more severe and frequent. Leucine (11) . Peptides were labeled with 12-I (Industrial Nuclear Co., St. Louis, Mo.) as described by Freychet et al. (12) . Free and total insulin and C-peptide immunoreactivities were measured by the procedures of Nakagawa et al. (13) and Kuzuva et al. (14) , respectively. To determine specific proinsulin (C-segment directed) antibodies, insulin antibodies were first removed by adsorption to insulin coupled covalently to Sepharose 4B (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.). The coupling procedure used cyanogen bromide-activated Sepharose 4B as described by Shapiro et al. (15) . Bovine, porcine, and human insulins, and bovine and porcine proinsulins and C-peptides were a generous gift from Dr. Ronald E. Chance of Eli Lilly and Co., Indianapolis, Ind.
RESULTS
The pertinent clinical features of the five patients with hypoglycemia are summarized in Table I . Neither a history of insulin therapy nor evidence of surreptitious self-administration of insulin could be elicited in these patients, despite a high level of suspicion by the medical staff. Typically, the finding ofhigh levels ofserum insulin by the double antibody radioimmunoassay led to the suspicion and demonstration of insulin antibodies. In this type of radioimmunoassay, the second antibody is specific for the animal-raised insulin antibody used in the assay, and therefore the 1251-insulin bound to the human insulin antibody ofthe serum sample will not be precipitated. As a result, less radioactivity is measured in the precipitate and spuriously higher insulin values are obtained from the standard curve.
Insulin acntibodies. Fig. 1 , pork insulin. Direct evidence regarding this point was derived from a detailed characterization of the antibody binding parameters. Scatchard plots of the insulin-antibody binding data showed bimodal distributions in all hypoglycemic and diabetic patients (Fig. 2) . Two classes of antibodies characterized by the high-affinity:lowcapacity and low-affinity:high-capacity sites were inferred from these plots. The association constants, binding capacities, and free energies of association for bovine, porcine, and human insulin in both groups of patients are shown in Tables II and III . No consistent differences in these parameters with regard to any species of insulin are apparent, and the overlap of values is complete for the hypoglycemic and diabetic patients. There is thus no consistent increase in affinity for human insulin in the antibodies of patients with hypoglycemia, and quantitative differences in antibody binding capacity cannot account for this syndrome.
Results of kinetic studies on the dissociation of insulin-antibody complexes indicate that the data can be fitted with Solid lines represent the least squares' linear fit ofthe binding data. The dashed line is the least squares' linear fit of the points related to the high-affinity antibody sites after subtraction ofthe contribution of the low-affinity antibody sites to the total binding in the corresponding range of insulin concentration. Association constants and binding capacities were calculated from the slopes and abscissa intercepts (16) , respectively. order dissociation rate constants for each class of antibodies are given in Table IV . Again, complete overlap in the values of these parameters in both groups of patients was found.
Plasma-free and total insulin and C-peptide. Average values of plasma glucose and frce and total insulin and C-peptide occurring during a standard oral GTT are presented in Table V . Peak values of free insulin in one of the patients (No. 4) were very high and were associated with symptomatic hypoglycemia 240 min after the administration of glucose. In the other three patients in whom free insulin concentrations were measured, the absolute values were not markedly elevated, but in two patients, the peak values occurred late at 120 min and remained elevated above levels obtained in healthy individuals during an oral GTT. The high levels of total C-peptide (Table V) in patient 2 correspond to proinsulin bound to insulin antibodies through its A-and B-chain antigenic determinants. Proinsulin (C-segment-directed) antibodies. The sera of hypoglycemic patients failed to show specific binding of bovine and(or) porcine proinsulins. Similarly, no specific binding of bovine and porcine C-peptides could be demonstrated (Table VI) . In constrast, the group of insulin-treated diabetics showed significant levels of specific binding of these peptides. Sera from all 10 patients bound bovine proinsulin, and in 9 of 10 patients porcine proinsulin was also bound. Only two of these diabetic patients had antibodies which bound bovine C-peptide, while four patients bound porcine C-peptide (Table VI) .
DISCUSSION
We have described five patients who presented with fasting and(or) postprandial hypoglycemic episodes.
When their serum insulin levels were measured by immunoassay, spuriously high values as a result of the presence of insulin antibodies were found. Seven other patients with similar clinical and laboratory features have been described (4) (5) (6) (7) (8) (9) . In all of these cases, the more conventionally recognized causes of hypoglycemia were excluded, and a differential diagnosis between factitious and autoimmune hypoglycemia remained.
An autoimmune origin for the insulin antibodies in patients with this syndrome was initially suggested by the lack of evidence of previous insulin administration (4-9). A similar situation also pertains to the five hypoglycemic patients described in this series. Despite many months of observation and a high level of suspicion regarding the possibility ofexogenous insulin injection, no evidence to support this diagnosis was forthcoming. The only possible exception in this regard was the second patient, who had received monthly treatments of intramuscular vitamin B12. These injections had been administered by the patient's mother, who is an insulin- requiring diabetic. The possibility that insulin-contaminated syringes might have been used in this patient cannot be excluded with certainty. However, the absence in her serum of C-segment-directed proinsulin antibodies, which might have arisen in response to the small amounts of proinsulin present in commercial insulin preparations, renders this possibility less likely (vide infra). Previous studies (4, 5, 7, 8) have attempted to solve the diagnostic dilemma of factitious vs. an autoimmune basis for the development of insulin antibodies by performing competition studies in which radiolabeled porcine and bovine insulin were displaced from specific antibody sites by unlabeled porcine, bovine, and(or) human insulin. The displacement curves obtained with antibodies from these hypoglycemic patients have been interpreted as indicating a higher affinity for human insulin. However, the differences noted in the competition experiments were small, and detailed control studies were not made with antibodies generated in response to the administration of therapeutic preparations of insulin. Contrary to these previous reports, competition experiments and direct measurements of the association constants and binding capacities ofinsulin antibodies from the hypoglycemic patients and the control group of insulin-treated diabetics demonstrated no consistent differences for bovine, porcine, and human insulins. Therefore, no distinctioni between autoimmune and factitious hypoglycemia would seem to be possible on this basis. Commercial preparations of mixtures of bovineporcine insulin have small and variable amounts of contaminating bovine and porcine proinsulin (17) (18) (19) (20) . The se(quences of the C-segments of the precursor molecules differ from each other and from their human counterpart to a much larger extent than the insulin A and B chains (18, 21, 22) and have been shown to be potent antigens in both experimental animals (23) (24) (25) (26) and humans (27) (28) (29) (30) . A survey of insulin-treated diabetic patients demonstrated specific proinsulin antibodies in 80% of the cases (29) . Our results have confirmed and extended this finding that C-segmentdirected proinsulin antibodies were detected in the sera of 100 and 90% of the insulin-treated diabetics tested with bovine and porcine proinsulins, respectively. In addition, bovine and porcine C-peptide specific antibodies were present in the sera of 20 and 40% of the diabetic patients, respectively. The reason for the higher frequency of proinsulin-directed antibodies cannot be accounted for by the insulin A-and B-chain antigenic determinants in the proinsulin molecule, because these antibodies were completely removed from the sera by adsorption to insulin coupled covalently to Sepharose beads. Conformation-dependent antigenic determi- pool of antibody-bound insulin can proceed at maximal rates of 0.09-1.47 and 0.56-6.56%/min, for the highand low-affinity antibodies, respectively (Table IV) . If the pool of antibody-bound insulin is large enough, substantial amounts of free hormone can be released by this mechanism (35) . Unlike insulin that is secreted by the pancreas, a hormone dissociating from circulating insulin-antibody complexes is not under feed-back control and may thus give rise to hypoglycemic episodes. A similar mechanism has been invoked to explain the recurrent hypoglycemia and absence of insulin requirements in one ketosis-prone diabetic (36) . Because of the first order character of the dissociation reaction, the absolute amount of insulin released per unit oftime from the pool of bound hormone will be directly proportional to the concentration of bound hormone. It is possible that the higher frequency ofthese episodes in the autoimmune group of patients may be accounted for by insulin dissociating from its antibodies at times when their blood sugar is within the normal range as compared with the raised glucose values which usuallv prevail in diabetic patients. In addition, factors such as insulin resistance and secretion of contrainsulin hormones may also determine whether or not hypoglycemia will occur at a particular time. Furthermore, an enhanced output of insulin in the presence of insulin antibodies has been documented in vitro with isolated rat islet tissue (37) . This circumstance may contribute to the hypoglycemic syndrome, although clearly the secreted insulin would be bound by antibodies, and dissociation would still be required for its hypoglycemic action. Also, the rapid binding of newly secreted insulin by circulating antibodies may prevent the immediate action of the hormone and thus result in delayed meta- Free insulin, ,U/ml 5 16 44 -74 38 14 7 Total insulin, /XU/ml (38, 39) , it is likely that a population ofdiabetics with substantial beta-cell reserve and significant insulin-antibody titers will exist. A note of caution seems in order in view of the possibility of hypoglycemia resulting from dissociation of insulinantibody complexes in such patients.
At present, the etiology of the syndrome of autoimmune hypoglycemia is unknown. Circulating antibodies directed against pancreatic islet cells have been demonstrated in the majority of patients with juvenile-onset diabetes (40) , and insulin-receptor antibodies have been identified in a group of patients with marked insulin resistance (41) . Specific antibodies to thyroid (42) , adrenal, and ovarian cells (43) occur in patients with hypofunction in these glands. Similarly, autoantibodies to a wide variety of other body constituents such as lipoproteins (44) , erythrocyte membranes (45), hepatic cell constituents (46, 47) , platelets (48) (49) . In this context it seems reasonable to accept the possibility that antibodies to insulin may arise spontaneously. However, because of the widespread availability of insulin, and our inability to specifically exclude exogenous administration, absolute proof of either of these alternatives is not forthcoming with currently available methods. Irrespective of the initial immunogenic stimulus, it is clear that the development of insulin antibodies in these patients may result in severe and even life-threatening hypoglycemic episodes. Furthermore, in all conditions associated with autoantibodies, the common denominator is a loss of immune tolerance resulting in the synthesis of self-directed antibodies and(or) the development of self-directed, delayed hypersensitivity. In this sense the syndrome of hypoglycemia with associated insulin antibodies fulfills the criteria defining autoimmunity and, as true for all autoimmune diseases, it remains to be proven whether the primary pathogenic mechanism is exogenous or endogenous in origin.
